Evidence map›Paper›PMID 37669225›Full record

ArticleThe Journal of infectious diseases2023

Report of the Assay Guidance Workshop on 3-Dimensional Tissue Models for Antiviral Drug Development.

Robert Jordan, Stephanie L Ford-Scheimer, Rodolfo M Alarcon, Anthony Atala, Jeffrey T Borenstein, Kyle R Brimacombe, Sara Cherry, Hans Clevers, Mindy I Davis, Simon G P Funnell and 18 more

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Robert JordanBill and Melinda Gates Foundation, Seattle, Washington, USA.
Stephanie L Ford-ScheimerNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA.
Rodolfo M AlarconNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Anthony AtalaWake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.ORCID 0000-0001-8186-2160
Jeffrey T BorensteinDraper Laboratory, Cambridge, Massachusetts, USA.ORCID 0000-0002-4482-3274
Kyle R BrimacombeNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA.ORCID 0000-0002-9629-1417
Sara CherryDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-3956-6610
Hans CleversHubrecht Institute, Utrecht, The Netherlands.
Mindy I DavisNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-9557-7376
Simon G P FunnellUK Health Security Agency, Salisbury, United Kingdom.ORCID 0000-0002-4254-2751
Lee GehrkeInstitute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Linda G GriffithDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Abigail C GrossmanNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA.
Thomas HartungDepartment of Environmental Health and Engineering, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0003-1359-7689
Donald E IngberHarvard Medical School, Boston, Massachusetts, USA.
Nicole C KleinstreuerNational Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle, North Carolina, USA.
Calvin J KuoDepartment of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California, USA.
Emily M LeeNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA.
Christine L MummeryLeiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-4549-6535
Thames E PickettNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Sasirekha RamaniDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0001-5631-8534
Edwin A Rosado-OlivieriRumiViro, RUMI Scientific, Inc, New York, New York, USA.ORCID 0000-0003-4756-0956
Evi B StrubleUS Food and Drug Administration, Silver Spring, Maryland, USA.ORCID 0000-0003-2068-4174
Zhengpeng WanDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.ORCID 0000-0001-5626-7722
Mark S WilliamsNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Matthew D HallNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA.ORCID 0000-0002-5073-442X
Marc FerrerNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA.
Sarine MarkossianNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA.ORCID 0000-0003-4042-0264

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The National Center for Advancing Translational Sciences (NCATS) Assay Guidance Manual (AGM) Workshop on 3D Tissue Models for Antiviral Drug Development, held virtually on 7-8 June 2022, provided comprehensive coverage of critical concepts intended to help scientists establish robust, reproducible, and scalable 3D tissue models to study viruses with pandemic potential. This workshop was organized by NCATS, the National Institute of Allergy and Infectious Diseases, and the Bill and Melinda Gates Foundation. During the workshop, scientific experts from academia, industry, and government provided an overview of 3D tissue models' utility and limitations, use of existing 3D tissue models for antiviral drug development, practical advice, best practices, and case studies about the application of available 3D tissue models to infectious disease modeling. This report includes a summary of each workshop session as well as a discussion of perspectives and challenges related to the use of 3D tissues in antiviral drug discovery.

Indexed as

Antiviral AgentsDrug DiscoveryBiological AssayAntiviral Agents3D tissue modelsantiviral drug discoverybody-on-a-chiphuman pluripotent stem cells (hPSCs)induced pluripotent stem cells (iPSCs)microphysiological systems (MPS)organoidorgan-on-a-chipSARS-CoV-2tissue-derived stem cells

Identifiers

PMID37669225
PMCPMC10547463

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.